Navigation Links
Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
Date:10/19/2008

TR-701 Phase 1 Clinical Trial Results Disclosed

SAN DIEGO, Oct. 20 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing "Best-in-Class" drugs for the treatment of serious bacterial infections, announced today that the results of multiple studies on its lead program, TR-701, and its other pipeline programs will be presented in eighteen presentations at the upcoming joint Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Diseases Society of America (IDSA) meeting in Washington, DC. Thirteen of the presentations focus on TR-701, a second generation oxazolidinone that recently commenced Phase 2 clinical studies.

"Acceptance of these presentations by the ICAAC committee highlights the interest in and value of the TR-701 program, the Trius pipeline, and our underlying technologies," stated Jeffrey Stein, Ph.D., President and CEO of Trius Therapeutics. "We are especially pleased to provide details of our TR-701 Phase 1 clinical trial results that support the once-daily dosing and short course of therapy in our recently initiated Phase 2 study in complicated skin and skin structure infections (cSSSIs). It is also exciting to see that the results of studies by external investigators demonstrate the drug's increased potency and expanded spectrum of activity."

The presentations are as follows:

Saturday, October 25th

(Poster Summary Session, Ballroom A/B, 10:00 am - 12:00 pm)

-- Oral Presentation: Overview of TR-701 and TR-700 Posters and

Presentations

(Poster Session 23, 12:15 pm - 1:15 pm)

-- F1-334: Discovery and SAR of a Novel Series of Pyrimidine Antibacterials

Targeting Methionyl-tRNA Synthase (MetRS)

-- F1-335: In Vitro Activity of Rx100472 Against Clinically Important

Bacteria

-- F1-336: Advanced Microbiology Study of Rx100472, A Novel Methionyl-tRNA

Synthetase (MetRS) inhibi
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
2. PacificGMP Completes GMP Product Fill for Trius Therapeutics
3. Trius Doses First Patient in Antibacterial Phase 2 Trial
4. For Most, Good Oral Care Does More Than Antibiotics to Prevent Dental-Related Heart Problems, Reports the Harvard Heart Letter
5. ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics
6. Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity
7. SuperGens Novel Hypomethylating Agent Highlighted at AACR Plenary Session
8. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
9. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
10. Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening
11. ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/686gwf/investigation ... Report on China,s Bevacizumab Market ,2010-2019" report to ... trade name of Avastin, bevacizumab injection is the first ... was approved by CFDA to treat metastatic colorectal cancer. ... all come from Roche and its subsidiary Genectech. ...
(Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Quetiapine ... Developed by AstraZeneca plc, quetiapine (under the ... for the treatment of schizophrenia. Approved by CFDA ... in the Catalogue of Drugs for the Basic ...
(Date:8/28/2015)... Aug. 28, 2015  IP Shakti, LLC, today announced that ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... "Our new corporate identity signifies our transformation into a company ... analytics platform for patent claim validity." ... the proprietary AIA Shield™ platform, the Company commenced a corporate ...
Breaking Medicine Technology:Investigation Report on China's Bevacizumab Market 2015-2019 2China Quetiapine Market Investigation Report 2010-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
... Tenn., Aug. 30 ,Palatin Technologies, Inc. (Amex: ... ) announced today that they have delayed plans ... bremelanotide, a first in class,melanocortin agonist drug candidate, ... decision follows responses from representatives of,the U.S. Food ...
... FRANCISCO, Calif., Aug. 29 ,Exelixis, Inc. (Nasdaq: EXEL ... for analysts and investors in conjunction with the International,Association ... Conference on,Lung Cancer. The webcast will be held on ... During the webcast, Exelixis management will,discuss data from a ...
Cached Medicine Technology:King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction 2Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing 2
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... For Dallas, ... is taking part with their subsidiary USPI Tenet Health. , The American Heart Association ... heart disease and stroke. They believe that together, a difference can be made. Walkers ...
(Date:8/28/2015)... ... ... The 6th Annual Survivor in the City, Chicago silent auction and cocktail ... its cadre of widespread support—an official letter of support and gratitude from the Mayor ... and the University of Illinois at Chicago’s Department of Neurosurgery, the Brain Aneurysm Foundation ...
(Date:8/28/2015)... ... ... Saint Petersburg, FL —Pocket Protein™, a protein beverage that ... lactose or caffeine in a convenient 2 oz. pouch that never needs refrigeration, ... , Five consumer packaged goods (CPG) products were selected by the SupplySide editorial ...
(Date:8/28/2015)... Boynton Beach, FL. (PRWEB) , ... August 28, ... ... creating problems for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new ... Strawbridge believes that it should begin with the employer and employees getting together ...
(Date:8/28/2015)... ... 28, 2015 , ... CARF International announced that West Ridge ... treatment and intensive family based services. , By pursuing and achieving accreditation, West ... of excellence. As a nonprofit charity for more than 50 years, West Ridge ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2
... Cellular damage induced by oxygen free radicals may be ... new study. //This groundbreaking study conducted by neuroscientists at ... of complex I, a protein that plays a major ... has been blamed for cellular damage in Parkinson’s disease. ...
... yet ascertained the top floors of the Melbourne office block ... the cause of illnesses.// ,Tests on radiofrequency emissions, ... any link as yet to the seven cases of brain ... of these seven cases were employees who had worked on ...
... genetic disorder which completely affects the immune system. In ... //therapy was successfully used to cure this life threatening ... Of Veterinary Medicine and the National Institute of Allergy ... as a vector for the correct gene of XSCID. ...
... of several previous studies of TNF- (tumor necrosis factor) ... that use of these drugs causes an increased risk ... study shows a strong association between treatment with TNF-blocking ... pneumonia, and cancers,' says Eric Matteson, M.D., Mayo Clinic ...
... a pigment that imparts tomatoes its characteristic red color ... ideal for prevention of strokes and heart attacks.// Previous ... chemical. ,According to scientists, the stickiness of ... - was reduced by 70 percent when 220 volunteers ...
... issue of Cancer Cell says that scientists have identified ... how cancer progresses.// This molecule was found to inhibit ... vivo as well as in vitro. , ,This ... inhibitors must display a broad reactivity to effectively attenuate ...
Cached Medicine News:Health News:Oxygen-Induced Damage A Leading Cause For Parkinson’s Diseas 2Health News:In-Vivo Gene Therapy Technique to Cure XSCID in Basset Pups 2Health News:In-Vivo Gene Therapy Technique to Cure XSCID in Basset Pups 3Health News:Risk of Cancer from Drugs for Rheumatoid Arthritis 2Health News:Risk of Cancer from Drugs for Rheumatoid Arthritis 3Health News:Discovery Of New Molecule Could Solve Cancer Spread Mystery 2
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
... hand-held, point-of-care device for the qualitative detection of ... The TOX/See device can detect up to nine ... to 8 minutes and requires only a few ... packaged to maximize convenience and ease of use. ...
... is a 1-step, hand-held, point-of-care device for the ... human urine. The TOX/See device can detect ... drugs in 3 to 8 minutes and requires ... cassette is individually packaged to maximize convenience and ...
Medicine Products: